R&D News | pharmaphorum

News

iRhythm wearable heart monitor raises AFib diagnoses by 52%

Screening people in primary care with a wearable heart monitor developed by iRhythm was able to increase diagnoses of atrial fibrillation (AFib) by 52%, although it did not result in a redu

News

Two of three trials fail, but Sanofi will still file MS drug

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of thr

News

Kerendia works in heart failure, but how might it be used?

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but th

News

Alnylam hails vutrisiran data, but investors seem sceptical

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems t

News

UK biotech ReNeuron quits AIM as financing push fails

ReNeuron has become the latest UK biotech planning to cancel its listing on the AIM exchange, saying it has been unable to raise the capital it desperately needs to keep its business afloat

News

BioMarin's change in direction claims more jobs

The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.

iRhythm wearable heart monitor raises AFib diagnoses by 52%

Two of three trials fail, but Sanofi will still file MS drug

Kerendia works in heart failure, but how might it be used?

Alnylam hails vutrisiran data, but investors seem sceptical

UK biotech ReNeuron quits AIM as financing push fails

BioMarin's change in direction claims more jobs

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks